ARTICLE | Clinical News

Priority Review for Indivior's RBP-6000

August 4, 2017 7:52 PM UTC

Indivior plc (LSE:INDV) said FDA accepted and granted Priority Review to an NDA for RBP-6000 to treat adults with moderate to severe opioid use disorder. Its PDUFA date is Nov. 30. The product is under review as part of a complete treatment plan that includes counseling and psychosocial support.

The company said FDA will hold an advisory committee meeting to discuss the application, which will likely take place in 4Q17...

BCIQ Company Profiles

Indivior plc